Lesson plan
IBMX
IBMX (3-isobutyl-1-methylxanthine), like other methylxanthine derivatives, is both a: # competitive non-selective phosphodiesterase inhibitor which raises intracellular cAMP, activates PKA, inhibits TNFα and leukotriene synthesis, and reduces inflammation and innate immunity, and # nonselective adenosine receptor antagonist. As a phosphodiesterase inhibitor, IBMX has IC 50 = 2–50 μM and does not inhibit PDE8 or PDE9.
Article summary
IBMX (3-isobutyl-1-methylxanthine), like other methylxanthine derivatives, is both a: # competitive non-selective phosphodiesterase inhibitor which raises intracellular cAMP, activates PKA, inhibits TNFα and leukotriene synthesis, and reduces inflammation and innate immunity, and # nonselective adenosine receptor antagonist. As a phosphodiesterase inhibitor, IBMX has IC 50 = 2–50 μM and does not inhibit PDE8 or PDE9.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.